184 related articles for article (PubMed ID: 38164653)
1. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis.
Cha DS; Kleine N; Teopiz KM; Di Vincenzo JD; Ho R; Galibert SL; Samra A; Zilm SPM; Cha RH; d'Andrea G; Gill H; Ceban F; Meshkat S; Wong S; Le GH; Kwan ATH; Rosenblat JD; Rhee TG; Mansur RB; McIntyre RS
Expert Opin Pharmacother; 2024; 25(1):5-14. PubMed ID: 38164653
[TBL] [Abstract][Full Text] [Related]
2. Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABA
Sharma R; Bansal P; Saini L; Sharma N; Dhingra R
Pharmacol Biochem Behav; 2024 May; 238():173734. PubMed ID: 38387651
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of zuranolone for the treatment of depression: A systematic review and meta-analysis.
Li Z; Wu Q; Peng P; Wu M; Liu S; Liu T
Psychiatry Res; 2024 Jan; 331():115640. PubMed ID: 38029628
[TBL] [Abstract][Full Text] [Related]
4. The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials.
Clayton AH; Suthoff E; Jain R; Kosinski M; Fridman M; Deligiannidis KM; Meltzer-Brody S; Chen SY; Gervitz L; Huang MY; Trivedi M; Bonthapally V
J Affect Disord; 2024 Apr; 351():904-914. PubMed ID: 38325605
[TBL] [Abstract][Full Text] [Related]
5. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial.
Deligiannidis KM; Meltzer-Brody S; Gunduz-Bruce H; Doherty J; Jonas J; Li S; Sankoh AJ; Silber C; Campbell AD; Werneburg B; Kanes SJ; Lasser R
JAMA Psychiatry; 2021 Sep; 78(9):951-959. PubMed ID: 34190962
[TBL] [Abstract][Full Text] [Related]
6. Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression.
Barnes KN; Vogl CM; Nelson LA
Ann Pharmacother; 2024 Jul; 58(7):728-734. PubMed ID: 37876133
[TBL] [Abstract][Full Text] [Related]
7. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
Walkery A; Leader LD; Cooke E; VandenBerg A
Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis.
Winslow M; White E; Rose SJ; Salzer E; Nemec EC
Int J Clin Pharm; 2024 Jun; 46(3):590-601. PubMed ID: 38489051
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder.
Meshkat S; Teopiz KM; Di Vincenzo JD; Bailey JB; Rosenblat JD; Ho RC; Rhee TG; Ceban F; Kwan ATH; Cao B; McIntyre RS
J Affect Disord; 2023 Nov; 340():893-898. PubMed ID: 37557991
[TBL] [Abstract][Full Text] [Related]
10. Exploring the clinical potentials of zuranolone in managing postpartum depression: A new therapeutic horizon.
Nashwan AJ; Rehan ST; Imran L; Abbas SG; Khan SF
Prog Neuropsychopharmacol Biol Psychiatry; 2024 Jun; 132():110983. PubMed ID: 38412941
[TBL] [Abstract][Full Text] [Related]
11. Zuranolone: A Narrative Review of a New Oral Treatment for Postpartum Depression.
Hitt EM
Clin Ther; 2024 May; 46(5):433-438. PubMed ID: 38697873
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of zuranolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States.
O'Callaghan L; Chertavian E; Johnson SJ; Ferries E; Deligiannidis KM
J Med Econ; 2024; 27(1):492-505. PubMed ID: 38465615
[TBL] [Abstract][Full Text] [Related]
13. Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder.
Arnaud A; Suthoff E; Stenson K; Werneburg B; Hodgkins P; Bonthapally V; Jonas J; Meyer K; O'Day K
J Affect Disord; 2021 Apr; 285():112-119. PubMed ID: 33640861
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.
Parikh SV; Aaronson ST; Mathew SJ; Alva G; DeBattista C; Kanes S; Lasser R; Bullock A; Kotecha M; Jung J; Forrestal F; Jonas J; Vera T; Leclair B; Doherty J
Neuropsychopharmacology; 2024 Jan; 49(2):467-475. PubMed ID: 37875578
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials.
Zou J; Yang L; Yang G; Gao J
Psychiatry Res; 2023 Oct; 328():115450. PubMed ID: 37683318
[TBL] [Abstract][Full Text] [Related]
16. Zuranolone for the Treatment of Postpartum Depression.
Deligiannidis KM; Meltzer-Brody S; Maximos B; Peeper EQ; Freeman M; Lasser R; Bullock A; Kotecha M; Li S; Forrestal F; Rana N; Garcia M; Leclair B; Doherty J
Am J Psychiatry; 2023 Sep; 180(9):668-675. PubMed ID: 37491938
[TBL] [Abstract][Full Text] [Related]
17. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA
Althaus AL; Ackley MA; Belfort GM; Gee SM; Dai J; Nguyen DP; Kazdoba TM; Modgil A; Davies PA; Moss SJ; Salituro FG; Hoffmann E; Hammond RS; Robichaud AJ; Quirk MC; Doherty JJ
Neuropharmacology; 2020 Dec; 181():108333. PubMed ID: 32976892
[TBL] [Abstract][Full Text] [Related]
18. Zuranolone: First Approval.
Heo YA
Drugs; 2023 Nov; 83(16):1559-1567. PubMed ID: 37882942
[TBL] [Abstract][Full Text] [Related]
19. Development of neuroactive steroids for the treatment of postpartum depression.
Gunduz-Bruce H; Takahashi K; Huang MY
J Neuroendocrinol; 2022 Feb; 34(2):e13019. PubMed ID: 34462985
[TBL] [Abstract][Full Text] [Related]
20. Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression.
Deligiannidis KM; Citrome L; Huang MY; Acaster S; Fridman M; Bonthapally V; Lasser R; Kanes SJ
J Clin Psychiatry; 2023 Jan; 84(1):. PubMed ID: 36724109
[No Abstract] [Full Text] [Related]
[Next] [New Search]
